Literature DB >> 35510094

Successful Use of Aspirin, Apixaban, and Viscoelastography in a Patient with Severe COVID Disease and Allergy to Porcine Products.

Jacob A Reeder1, Tessa R Reynolds1, Brian W Gilbert1.   

Abstract

Coagulation abnormalities are frequently described in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Common thromboprophylaxis and anticoagulation treatment strategies include the use of heparinoid therapy. We describe a 57-year-old woman with an allergy to porcine products that was started on apixaban for anticoagulation therapy given her allergy profile and need for venous thromboembolism prophylaxis. Apixaban and aspirin therapy were optimized with the support of serial viscoelastography and platelet function assays. Our patient experienced respiratory failure requiring intubation for 7 days but was successfully weaned to room air, tolerated a regular diet, and ultimately discharged to home after a 17-day hospital course. Here we report the safe and successful use of aspirin, apixaban, and viscoelastography for COVID-19-associated coagulopathy.
© The Author(s) 2021.

Entities:  

Keywords:  allergy; anticoagulants; critical care

Year:  2021        PMID: 35510094      PMCID: PMC7862914          DOI: 10.1177/0018578721990898

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  7 in total

1.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.

Authors:  Ning Tang; Huan Bai; Xing Chen; Jiale Gong; Dengju Li; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-04-27       Impact factor: 5.824

Review 2.  Tracing the Lines: A Review of Viscoelastography for Emergency Medicine Clinicians.

Authors:  Brian W Gilbert; Brittany D Bissell; Ruben D Santiago; Megan A Rech
Journal:  J Emerg Med       Date:  2020-05-14       Impact factor: 1.484

3.  Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia.

Authors:  Songping Cui; Shuo Chen; Xiunan Li; Shi Liu; Feng Wang
Journal:  J Thromb Haemost       Date:  2020-05-06       Impact factor: 5.824

4.  Deep Vein Thrombosis among Intensive Care Unit Patients; an Epidemiologic Study.

Authors:  MirMohammad Miri; Reza Goharani; Mohammad Sistanizad
Journal:  Emerg (Tehran)       Date:  2017-01-09

5.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19.

Authors:  F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D A M P J Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman
Journal:  Thromb Res       Date:  2020-04-10       Impact factor: 3.944

Review 6.  Coagulopathy of Coronavirus Disease 2019.

Authors:  Toshiaki Iba; Jerrold H Levy; Marcel Levi; Jean Marie Connors; Jecko Thachil
Journal:  Crit Care Med       Date:  2020-09       Impact factor: 9.296

7.  COVID-19 and its implications for thrombosis and anticoagulation.

Authors:  Jean M Connors; Jerrold H Levy
Journal:  Blood       Date:  2020-06-04       Impact factor: 25.476

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.